cannabidivarin and cannabigerol

cannabidivarin has been researched along with cannabigerol* in 4 studies

Other Studies

4 other study(ies) available for cannabidivarin and cannabigerol

ArticleYear
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2022, Volume: 170

    Cannabis is well established as possessing immune modulating activity. The objective of this study was to evaluate the anti-inflammatory properties of selected cannabis-derived terpenes and cannabinoids. Based on their activity in cannabis-chemovar studies, α-pinene, trans-nerolidol, D-limonene, linalool and phytol were the selected terpenes evaluated. The cannabinoid compounds evaluated included cannabidivarin, cannabidiol, cannabinol, cannabichromene, cannabigerol and delta-9-tetrahydrocannabinol. Human PBMC were pretreated with each compound, individually, at concentrations extending from 0.001 to 10 μM and then stimulated with CpG (plasmacytoid dendritic cell), LPS (monocytes), or anti-CD3/CD28 (T cells). Proliferation, activation marker expression, cytokine production and phagocytosis, were quantified. Of the 21 responses assayed for each compound, cannabinoids showed the greatest immune modulating activity compared to their vehicle control. Delta-9-tetrahydrocannabinol possessed the greatest activity affecting 11 immune parameters followed by cannabidivarin, cannabigerol, cannabichromene, cannabinol and cannabidiol. α-Pinene showed the greatest immune modulating activity from the selected group of terpenes, followed by linalool, phytol, trans-nerolidol. Limonene had no effect on any of the parameters tested. Overall, these studies suggest that selected cannabis-derived terpenes displayed minimal immunological activity, while cannabinoids exhibited a broader range of activity. Compounds possessing anti-inflammatory effects may be useful in decreasing inflammation associated with a range of disorders, including neurodegenerative disorders.

    Topics: Cannabidiol; Cannabinoids; Cannabinol; Cannabis; Dronabinol; Humans; Leukocytes, Mononuclear; Phytol; Terpenes

2022
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood-Brain Barrier Under Ischemic Conditions.
    Cannabis and cannabinoid research, 2021, Volume: 6, Issue:4

    Topics: Blood-Brain Barrier; Cannabinoids; Endothelial Cells; Humans; Vascular Endothelial Growth Factor A

2021
Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ
    Analytical chemistry, 2017, 04-18, Volume: 89, Issue:8

    Topics: Animals; Cannabidiol; Cannabinoids; Chromatography, High Pressure Liquid; Colitis; Colon; Dronabinol; Limit of Detection; Male; Mice; Mice, Inbred ICR; Pancreas; Tandem Mass Spectrometry

2017
Epigenetic control of skin differentiation genes by phytocannabinoids.
    British journal of pharmacology, 2013, Volume: 170, Issue:3

    Endocannabinoid signalling has been shown to have a role in the control of epidermal physiology, whereby anandamide is able to regulate the expression of skin differentiation genes through DNA methylation. Here, we investigated the possible epigenetic regulation of these genes by several phytocannabinoids, plant-derived cannabinoids that have the potential to be novel therapeutics for various human diseases.. The effects of cannabidiol, cannabigerol and cannabidivarin on the expression of skin differentiation genes keratins 1 and 10, involucrin and transglutaminase 5, as well as on DNA methylation of keratin 10 gene, were investigated in human keratinocytes (HaCaT cells). The effects of these phytocannabinoids on global DNA methylation and the activity and expression of four major DNA methyltransferases (DNMT1, 3a, 3b and 3L) were also examined.. Cannabidiol and cannabigerol significantly reduced the expression of all the genes tested in differentiated HaCaT cells, by increasing DNA methylation of keratin 10 gene, but cannabidivarin was ineffective. Remarkably, cannabidiol reduced keratin 10 mRNA through a type-1 cannabinoid (CB1 ) receptor-dependent mechanism, whereas cannabigerol did not affect either CB1 or CB2 receptors of HaCaT cells. In addition, cannabidiol, but not cannabigerol, increased global DNA methylation levels by selectively enhancing DNMT1 expression, without affecting DNMT 3a, 3b or 3L.. These findings show that the phytocannabinoids cannabidiol and cannabigerol are transcriptional repressors that can control cell proliferation and differentiation. This indicates that they (especially cannabidiol) have the potential to be lead compounds for the development of novel therapeutics for skin diseases.

    Topics: Cannabidiol; Cannabinoids; Cell Differentiation; Cell Line; DNA Methylation; DNA Methyltransferase 3A; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Epigenesis, Genetic; Humans; Keratin-1; Keratin-10; Keratinocytes; Phytochemicals; Protein Precursors; RNA, Messenger; Skin; Transcription, Genetic; Transglutaminases

2013